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a speciﬁc cancer histological subtype, that may be predictive of the 
clinical outcome of a patient, that are associated with the response 
to a particular therapeutic modality, or that provide insight into the 
general processes that are associated with the malignant phenotype. In 
most instances patients with surgically resectable lung cancer (stages 
I to III) have been utilized for these studies and data will be presented 
indicating that gene expression proﬁles can aid in identifying patients 
with early stage disease who currently receive only surgery that may 
also beneﬁt from adjuvant therapy. The proper design of these studies 
including the use of training and test sets of samples, validation of 
array data using alternate technologies such as real-time RT-PCR, and 
the validation of identiﬁed proﬁles or predictors using independent test 
sets will be discussed. Selected examples of large gene proﬁling studies 
will be presented including results from our group that examined 129 
squamous cell lung carcinomas (Raponi et al, Cancer Research, 2006) 
and a multi-institutional collaborative analysis that has recently proﬁled 
500 lung adenocarcinomas using oligonucleotide arrays. 
The proteomic analysis of lung cancers have to date utilized a wide 
variety of technologies and is a rapidly evolving area of investigation. 
Global analyses of lung cancer have included the use of two-dimen-
sional gel electrophoresis (2D-PAGE) for separation of tumor proteins 
with protein identiﬁcation using matrix-assisted laser desorption 
ionization mass spectrometry (MALDI-MS), as well as the use of the 
alternate technology of surface-enhanced laser desorption ionization 
mass spectrometry (SELDI-MS). Each tool has speciﬁc advantages and 
disadvantages which will be discussed. Speciﬁc subsets of proteins of 
interest in tumors such as cell signaling molecules and their activa-
tion state have and are being examined using antibody-based protein 
arrays as well as using tissue microarrays (TMAs) composed of large 
numbers of cores of parafﬁn-embedded lung cancers. TMAs have 
become a highly utilized tool that allows for not only validation of 
candidates identiﬁed with gene or protein proﬁling tools but also al-
lows for combined genomic-based analyses including ﬂuorescence in 
situ hybridization (FISH) to potentially identify the basis for candi-
date protein over-expression such as gene ampliﬁcation or deletion. 
Because of the disadvantages of current technologies investigators have 
begun utilizing liquid two dimensional-based methods for the separa-
tion of proteins from primary tissues such as lung cancers or cells. 
One technology incorporates the use of isobaric tagging (iTRAQ) of 
proteins and the 2D-liquid chromatography separation of proteins and 
fragments followed by tandem mass spectrometry of the tagged, pooled 
peptides. This has been recently used to deﬁne differentially expressed 
proteins associated with the epithelial-mesenchymal transition in lung 
cancer (Keshamouni et al, J Prot Res, 2006). Additional methods utilize 
liquid phase separation of proteins with chromatofocusing in the ﬁrst 
dimension and nonporous reverse phase (NPS-RP) HPLC in the second 
dimension, followed by ESI-TOF mass spectrometry to identify proteins 
differentially expressed. Advances in these tools will allow more de-
tailed analyses of the lung cancer proteome as the labor-intensive early 
technologies represent a serious disadvantage that limited their use. 
Additional proteomic technologies that have potential to aid in the early 
detection of lung cancer are approaches include the serological analysis 
of recombinant cDNA expression libraries of human tumors with 
autologous serum or (SEREX). SEREX has been used to demonstrate 
that the humoral immune response of cancer patients can be used to 
identify novel tumor antigens. Because of the SEREX approach is not 
conducive to the study of sera from hundreds of patients we developed 
a high-density phage-epitope microarray derived from the biopanning 
of a lung cancer phage display library (Chen et al, Cancer Research, 
2007). Similar approaches have been described by Zhong et al, Am 
J Resp Crit Care Med, 2005. Using a 2,304 element phage-epitope 
microarray, we interrogated a total of 250 sera from cancer patients and 
controls to develop an “autoantibody proﬁle” of lung adenocarcinoma. 
The phage-epitope microarray strategy facilitated easy identiﬁca-
tion of humoral response targets by phage-epitope cDNA sequencing 
and individual candidates including ubiquilin 1 were identiﬁed. This 
candidate was validated on an independent set of serum samples from 
another institution and suggested that autoantibodies may provide one 
additional proteomic-based method that is noninvasive and may have 
potential for early lung cancer detection. 
Genomic and proteomic strategies are rapidly evolving but will likely 
continue to improve upon our ability to more comprehensively and 
sensitively interrogate gene alterations and identify more speciﬁc can-
didate biomarkers in lung cancer. This will hopefully lead to improved 
patient survival by allowing early detection and effective targeting of 
the critical cellular pathways needed by lung cancer cells to survive and 
spread.
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Introduction
Bronchoscopy dates back to the early 19th century where rigid illumi-
nating tubes were used to examine the tracheobronchial tree.(1) Since 
the introduction of the ﬁberoptic bronchoscope by Shigeto Ikeda,(2) 
bronchoscopy has revolutionized the practice of pulmonary medicine. 
In lung cancer, due to advances in real-time imaging and catheter based 
techniques, bronchoscopy remains pivotal not only in diagnosis and 
staging but also allows therapeutic intervention for airway restoration 
in patients with central airway obstruction and treatment of early cen-
tral airway cancers. Flexible bronchoscopy has supplanted rigid bron-
choscopy as the preferred procedure except for better airway control in 
massive hemoptysis and deployment of certain stents. Since bronchos-
copy allows access to the lung, it is a tool that enables researchers to 
better understand lung carcinogenesis, to prognosticate by means of 
biomarkers as well as in monitoring tumor response to targeted therapy 
by in-vivo microdynamic imaging.(3-5) 
Diagnosis 
In patients suspected with lung cancer, integrated positron emission to-
mography (PET)/CT assists the bronchoscopist in the optimal selection 
of techniques to facilitate diagnosis and staging. Bronchial washing, 
brushing, endobronchial and transbronchial biopsy have variable yields 
depending on tumor location and accessibility.(6) The addition of 
needle aspiration for endobronchial, submucosal, peripheral pulmo-
nary lesion or peribronchial lymph node not only increases diagnostic 
yield, it is highly cost-effective by obviating further need for invasive 
interventions.(7;8) 
Multi-detector helical CT(9) that allows reformatting of axial images 
into 3-dimensional virtual bronchoscopy has led to more precise target-
ing of peripheral pulmonary nodules for biopsy via electromagnetic 
steering probe or ultrathin bronchoscope.(10-12) The sensor probe is 
guided towards the target, and tissue sampling performed with forceps, 
needle or curette via guide sheath or direct bronchoscopic visualiza-
tion.(11;12) Seemingly attractive, navigational bronchoscopy is not 
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real-time and patient?s respiration makes localization of small nodules 
measuring less than 2cm, in the lower lobes and close to the pleura 
challenging.(13) This has prompted the combined approach of navi-
gational bronchoscopy where the sensor probe guides the bronchos-
copist to the target and conﬁrmed with the real-time ultrasound before 
sampling.(14)
Staging
The main indication for transbronchial needle aspiration (TBNA) is in 
lung cancer staging. It is performed without real-time imaging which 
has resulted in variable yield (20-74%). With virtual PET/CT bronchos-
copy, TBNA yield could be increased by targeting PET positive lymph 
nodes and sites for puncture localized within tracheobronchial tree by 
the sensor probe.(11;15) 
Notably a major advance in mediastinal staging is the incorporation of 
curvilinear ultrasound to the tip of bronchoscope that allows real-time 
imaging of the lymph nodes. Coupled with color ﬂow Doppler, endo-
bronchial ultrasonography (EBUS) facilitates safe aspiration of medias-
tinal lymph nodes by avoiding surrounding vascular structures.(16-18) 
By combining EBUS with endoscopic ultrasound trans-esophageal 
sampling of enlarged mediastinal lymph nodes, they achieve a diag-
nostic accuracy comparable with mediastinoscopy but performed in a 
non-invasive manner. Both techniques provide access to hilar, pulmo-
nary ligament, para-esophageal and adrenal lymph nodes that would 
otherwise be inaccessible by mediastinoscopy.(16) 
Palliation Of Malignant Central Airway Obstruction
Malignant central airway obstruction is a signiﬁcant cause of morbid-
ity and mortality. Approximately 30% of patients with lung cancer 
will present with airway obstruction, and 35% of this group will die 
of complications such as hemoptysis, postobstuctive pneumonia, and 
asphyxia. Although imminent asphyxiation could be temporarily re-
lieved by endotracheal intubation and mechanical ventilation, recana-
lization of the airway by bronchoscopic methods and stent placement 
results in rapid relief of symptoms and allows time for the institution of 
chemo(radio)therapy for sustained palliation, improved quality of life 
and prolonged survival.(19) Therefore selection of a therapeutic strat-
egy depends on type of lesion (Fig 1), acuity of presentation, patient’s 
general health status and physician’s expertise (Fig 2). All techniques 
except deployment of certain stents can be performed with the ﬂex-
ible or rigid bronchoscope. However in massive hemoptysis, the rigid 
bronchoscope confers better airway control by allowing large volume 
suctioning and ventilation at the same time.
Early Lung Cancer Detection And Intervention
Despite advances in chemotherapeutics, 5 year survival of lung cancer 
remains dismal at 15%.(20) It is conceivable to assume better outcome 
if lung cancer can be diagnosed and treated early. Improved CT imag-
ing techniques can detect peripheral tumors, however for early central 
airway cancers, they are radiographically invisible and diagnosed by 
sputum cytology and bronchoscopy.(21) As these lesions show subtle 
changes such as slight redness, lack of lustre, granular in appearance 
and thickening with paleness, it is not surprising that only 30% are 
detected by white light bronchoscopy.(22) Moreover it is reported that 
pre-invasive lesions showing moderate and severe dysplasia have 11% 
and 40% risk of progression to lung cancer,(23) it is therefore impor-
tant to localize these early lesions.
Autoﬂuorescence Bronchoscopy 
When bronchial surface is illuminated by light, light can be absorbed, 
reﬂected, back scattered or induce ﬂuorescence. Reﬂectance imaging 
(eg white light bronchscopy) deﬁnes structural features of bronchial 
epithelium to discriminate normal from abnormal while autoﬂuores-
cence bronchoscopy (AF) depends on the concentration of ﬂuorophores 
in the bronchial tissue. Normal bronchial epithelium ﬂuoresces in green 
when illuminated by blue light, however, as it transforms through 
dysplasia, carcinoma in-situ to invasive cancer a progressive decrease 
in green ﬂuorescence due to increased epithelial thickness and tumor 
neovascularisation occurs, making these abnormal areas appear red. 
The spectral differences between 500-700nm for normal, preneoplastic 
and neoplastic tissues serve as basis for the development of AF-reﬂec-
tance imaging devices such as LIFE (Xilix Technologies, Canada), 
D-light (Karl Storz, Germany), and SAFE 1000/3000 (Pentax, Japan). 
Numerous studies have consistently demonstrated superiority of AF 
over white light bronchoscopy for the detection of pre-invasive lesions 
and early lung cancer.(24-27) Conventional bronchoscopy is highly 
speciﬁc while AF has a high false positive rate when bronchitis or 
airway inﬂammation is encountered. This lower speciﬁcity could lead 
to extensive biopsy and increased procedural time that might cause pa-
tient harm. Our recent evaluation of real-time simultaneous video- and 
autoﬂuorescence imaging with SAFE 3000 (Pentax, Japan) achieves 
satisfactory sensitivity (0.85) for pre-invasive lesions and improved 
speciﬁcity (0.94) for targeted biopsy leading to marked decrease in 
procedural time and better patient safety.(28) 
Bronchoscopic Treatment of Early Lung Cancer
Precise staging of early central airway cancer is extremely important 
for the selection of appropriate treatment. Although surgery is still the 
preferred option, many patients harboring these cancers have smoking 
related competing comorbidity that, place them in high surgical risk. 
Moreover 20-30% of these early cancers are multifocal(29) which 
emphasize the need for lung preservation surgery and curative broncho-
scopic techniques as attractive alternatives. 
The criteria of early central airway cancers suitable for bronchoscopic 
treatment must be radiographically occult without lymph node or 
distant metastasis. The squamous cell cancer should measure less than 
2cm in greatest dimension with visible distal margin, and conﬁned 
within the cartilaginous layer of the tracheobronchial tree.(21;30) 
Therefore the selection of patients suitable for bronchoscopic treatment 
must take into account tumor size and depth of bronchial wall invasion 
and the combined use of high resolution CT, PET, AF and EBUS aid in 
the accurate staging of these early cancers. Whether optical coherence 
tomography (OCT) and confocal micro-endoscopy will be more precise 
for tumor assessment require investigation.(31-35) 
Bronchoscopic techniques that have demonstrated good tumor response 
include photodynamic therapy,(36) endobronchial electrosurgery,(33) 
cryotherapy,(37) and HDR-brachytherapy.(38) 
Research
Bronchoscopy offers researchers a unique opportunity to gain insight 
into lung carcinogenesis. New diagnostic tools such as narrow band im-
aging(39) that delineates and characterises microvascular network aims 
at advancing the understanding of angiogenesis and its role in early 
carcinogenesis; Raman spectroscopy that measures biochemical com-
position and metabolic state of bronchial tissues attempts to improve 
accuracy in the differentiation of pre-invasive from benign lesions 
whilst confocal micro-endoscopy and OCT facilitate our understand-
ing in the evolution of pre-invasive lesions (40) by providing real-time 
non-invasive histologic imaging. 
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Conclusion
Sensitive bronchoscopic techniques and imaging enhance the under-
standing of lung carcinogenesis, and allow for early detection of lung 
cancers in individuals at risk. With improved cancer therapeutics, more 
patients will experience cure and longer periods of remission. In pa-
tients with malignant central airway obstruction, therapeutic bronchos-
copy remains an important form of palliation.
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Objectives: Discussing how the results of radiotherapy in NSCLC may 
be improved by optimizing fractionation, volume deﬁnition, and total 
doses to the tumor, while preserving the surrounding normal tissues. 
Abstract: Radiotherapy has become a major therapeutic option in tho-
racic oncology. The large accessibility of three-dimensional conformal 
techniques has allowed dose escalation and concurrent combination 
with chemotherapy to occur with acceptable toxicities. Efﬁcacy and 
feasibility of conformal radiotherapy may be improved by a better deﬁ-
nition of the tumor volumes and a ﬁnest focalisation of the ballistics. 
In this way, several issues are currently available, such as optimizing 
fractionation schemes and increasing total doses delivered to the tumor. 
New radiotherapy techniques have been evaluated in prospective 
studies, including respiratory gating, intensity modulation, which may 
allow even superior dose escalation and reduce normal tissues post-ra-
diation complications. In terms of technology, stereotaxic radiotherapy 
and protontherapy, are so far available in a few centers, and represent 
a formidable hope for improved results, especially for early stage lung 
tumors, with preliminary very encouraging results, jeopardizing the use 
of surgery in certain circumstances. These present and future develop-
ments make radiotherapy one of the most promising therapeutics in 
thoracic oncology, and will be presented during the session.
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PS2 patients usually account for a small proportion of patients enrolled 
in trials of ﬁrst-line treatment for advanced disease but represent a sig-
niﬁcantly higher proportion (up to 30%-40%) when population-based 
surveys are conducted . 
As in other types of cancer, PS has a clear prognostic role in advanced 
NSCLC. Median overall survival of patients with PS2, whatever the 
treatment under investigation, is always substantially shorter than that 
of PS0 or PS1 patients, and rarely exceeds 5 months , with 1-year sur-
vival rates <20%. A worse PS is characterised by lower response rates 
to chemotherapy and it is a widely held opinion that these unﬁt patients 
are at higher risk for severe toxicity.
For this sub-group of patients, there is no treatment widely accepted as 
standard and oncologists have to choose among several treatment op-
tions: best supportive care, single-agent chemotherapy, non-platinum-
based combination chemotherapy and platinum-based combination 
chemotherapy.
It is still unclear if the beneﬁt achieved with cisplatin-based chemother-
apy is restricted only to PS0 and PS1 patients, or also applies to PS2 
patients. In the meta-analysis published in 1995, although overall re-
sults were limited by statistical heterogeneity and evident outcome dif-
ferences for the different chemotherapy categories, a signiﬁcant beneﬁt 
was demonstrated for cisplatin-based trials, and a sub-group analysis 
conﬁrmed this beneﬁt for both good and poorer PS patients. However, 
the outcome of 64 PS2 patients enrolled in the clinical trial ECOG 1594 
comparing four platinum-based combinations has proven to be very 
poor. As for the role of carboplatin, the results of the CALGB 9730 
study, comparing paclitaxel plus carboplatin versus paclitaxel alone, 
must be considered. The study enrolled patients with a PS of between 
0 and 2. In the sub-group of PS2 patients median survival in the group 
treated with combination chemotherapy was signiﬁcantly longer than 
with paclitaxel alone. In a randomized phase II study carboplatin plus 
paclitaxel and cisplatin plus gemcitabine, administered at attenuated 
doses, proved to be feasible in PS 2 patients. After 1995, some advan-
tage of chemotherapy versus supportive care alone has been shown 
also with many new cytotoxic agents as gemcitabine, vinorelbine, 
paclitaxel and docetaxel, administered as single agents. These drugs 
are usually characterised by a good tolerability, with a low incidence 
of severe adverse events. Most of the studies show some advantage of 
chemotherapy in terms of overall survival also in the sub-group of PS2 
patients, although formal statistical comparisons are precluded by the 
low absolute number of patients. 
However, there is no consistent evidence that combination chemo-
therapy without platinum is better than third generation drugs given 
as single agents. An Italian randomised trial compared the combina-
tion of gemcitabine and vinorelbine to the two single drugs in patients 
>70 years of age , and the combination did not show advantage over 
mono-chemotherapy in terms of overall survival also in the sub-group 
of PS2 patients. The results of an European Experts Panel on the topic, 
